Reduced Global Efficiency and Random Network Features in Patients with Relapsing-Remitting Multiple Sclerosis with Cognitive Impairment

被引:13
|
作者
Hawkins, R. [1 ]
Shatil, A. S. [1 ]
Lee, L. [2 ]
Sengupta, A. [1 ]
Zhang, L. [1 ]
Morrow, S. [3 ]
Aviv, R., I [4 ,5 ,6 ]
机构
[1] Sunnybrook Hlth Sci Ctr, Dept Med Imaging, Toronto, ON, Canada
[2] Sunnybrook Hlth Sci Ctr, Dept Med, Div Neurol, Toronto, ON, Canada
[3] Univ Hosp, London Hlth Sci Ctr, Lawson Hlth Res Inst, Div Neurol, London, ON, Canada
[4] Univ Toronto, Inst Biomat & Biomed Engn, Toronto, ON, Canada
[5] Univ Ottawa, Dept Radiol, CPCR Bldg,Room L2121, Ottawa, ON K1H 1M2, Canada
[6] Ottawa Hosp, Div Neuroradiol, Ottawa, ON, Canada
关键词
STRUCTURAL CORTICAL NETWORKS; WHITE; DECLINE; PERFORMANCE; ATTENTION; PATHOLOGY; DISEASE; SPEED;
D O I
10.3174/ajnr.A6435
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
BACKGROUND AND PURPOSE: Graph theory uses structural similarity to analyze cortical structural connectivity. We used a voxel-based definition of cortical covariance networks to quantify and assess the relationship of network characteristics to cognition in a cohort of patients with relapsing-remitting MS with and without cognitive impairment. MATERIALS AND METHODS: We compared subject-specific structural gray matter network properties of 18 healthy controls, 25 patients with MS with cognitive impairment, and 55 patients with MS without cognitive impairment. Network parameters were compared, and predictive value for cognition was assessed, adjusting for confounders (sex, education, gray matter volume, network size and degree, and T1 and T2 lesion load). Backward stepwise multivariable regression quantified predictive factors for 5 neurocognitive domain test scores. RESULTS: Greater path length (r = ?0.28, P < .0057) and lower normalized path length (r = 0.36, P < .0004) demonstrated a correlation with average cognition when comparing healthy controls with patients with MS. Similarly, MS with cognitive impairment demonstrated a correlation between lower normalized path length (r = 0.40, P < .001) and reduced average cognition. Increased normalized path length was associated with better performance for processing (P < .001), learning (P < .001), and executive domain function (P = .0235), while reduced path length was associated with better executive (P = .0031) and visual domains. Normalized path length improved prediction for processing (R-2 = 43.6%, G(2) = 20.9; P < .0001) and learning (R-2 = 40.4%, G(2) = 26.1; P < .0001) over a null model comprising confounders. Similarly, higher normalized path length improved prediction of average z scores (G(2) = 21.3; P < .0001) and, combined with WM volume, explained 52% of average cognition variance. CONCLUSIONS: Patients with MS and cognitive impairment demonstrate more random network features and reduced global efficiency, impacting multiple cognitive domains. A model of normalized path length with normal-appearing white matter volume improved average cognitive z score prediction, explaining 52% of variance.
引用
收藏
页码:449 / 455
页数:7
相关论文
共 50 条
  • [21] Facial emotion recognition in patients with relapsing-remitting multiple sclerosis
    Fereydouni, Soodabe
    Hadianfard, Habib
    Ashjazadeh, Nahid
    NEUROLOGY ASIA, 2019, 24 (04) : 327 - 332
  • [22] Natalizumab use in pediatric patients with relapsing-remitting multiple sclerosis
    Arnal-Garcia, Carmen
    Rosa Garcia-Montero, Ma
    Malaga, Ignacio
    Millan-Pascual, Jorge
    Oliva-Nacarino, Pedro
    Ramio-Torrenta, Lluis
    Oreja-Guevara, Celia
    EUROPEAN JOURNAL OF PAEDIATRIC NEUROLOGY, 2013, 17 (01) : 50 - 54
  • [23] Alemtuzumab for the treatment of relapsing-remitting multiple sclerosis
    Hersh, Carrie M.
    Cohen, Jeffrey A.
    IMMUNOTHERAPY, 2014, 6 (03) : 249 - 259
  • [24] Alemtuzumab in the treatment of relapsing-remitting multiple sclerosis
    Fox, Edward J.
    EXPERT REVIEW OF NEUROTHERAPEUTICS, 2010, 10 (12) : 1789 - 1797
  • [25] Executive functions in relapsing-remitting multiple sclerosis
    Elosua, M. Rosa
    Villadangos, Noelia
    APPLIED NEUROPSYCHOLOGY-ADULT, 2023,
  • [26] Cladribine Tablets In Relapsing-Remitting Multiple Sclerosis
    Muir, Victoria J.
    Plosker, Greg L.
    CNS DRUGS, 2011, 25 (03) : 239 - 249
  • [27] Role of white matter in cognitive impairment among relapsing remitting multiple sclerosis patients
    Elkhooly, Mahmoud
    Bao, Fen
    Raghib, Muhammad
    Millis, Scott
    Bernitsas, Evanthia
    MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2023, 79
  • [28] Postural Control in Relapsing-Remitting Multiple Sclerosis
    Cusin, Flavia Salvaterra
    Tomaz, Andreza
    Gananca, Mauricio Malavasi
    Oliveira, Enedina Maria
    Falcao Goncalves, Alessandra Billi
    Caovilla, Heloisa Helena
    INTERNATIONAL ARCHIVES OF OTORHINOLARYNGOLOGY, 2022, 26 (04) : 592 - 604
  • [29] Ibudilast in relapsing-remitting multiple sclerosis A neuroprotectant?
    Barkhof, F.
    Hulst, H. E.
    Drulovic, J.
    Uitdehaag, B. M. J.
    Matsuda, K.
    Landin, R.
    NEUROLOGY, 2010, 74 (13) : 1033 - 1040
  • [30] Longitudinal cortical network reorganization in early relapsing-remitting multiple sclerosis
    Fleischer, Vinzenz
    Koirala, Nabin
    Droby, Amgad
    Gracien, Rene-Maxime
    Deichmann, Ralf
    Ziemann, Ulf
    Meuth, Sven G.
    Muthuraman, Muthuraman
    Zipp, Frauke
    Groppa, Sergiu
    THERAPEUTIC ADVANCES IN NEUROLOGICAL DISORDERS, 2019, 12